Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) Net Margin (2018 - 2023)

Endonovo Therapeutics has reported Net Margin over the past 9 years, most recently at 31597.24% for Q3 2023.

  • Quarterly results put Net Margin at 31597.24% for Q3 2023, down 2609213.0% from a year ago — trailing twelve months through Sep 2023 was 4632.17% (up 7262665.0% YoY), and the annual figure for FY2022 was 13649.17%, down 940200.0%.
  • Net Margin for Q3 2023 was 31597.24% at Endonovo Therapeutics, down from 4565.62% in the prior quarter.
  • Over the last five years, Net Margin for ENDV hit a ceiling of 758332.28% in Q4 2021 and a floor of 448894.43% in Q1 2022.
  • Median Net Margin over the past 5 years was 5352.88% (2019), compared with a mean of 10344.39%.
  • Biggest five-year swings in Net Margin: skyrocketed 77598715bps in 2021 and later plummeted -76897925bps in 2022.
  • Endonovo Therapeutics' Net Margin stood at 3815.94% in 2019, then tumbled by -363bps to 17654.87% in 2020, then soared by 4395bps to 758332.28% in 2021, then crashed by -101bps to 10646.97% in 2022, then crashed by -197bps to 31597.24% in 2023.
  • The last three reported values for Net Margin were 31597.24% (Q3 2023), 4565.62% (Q2 2023), and 567.47% (Q1 2023) per Business Quant data.